NCT01785602 - Efficacy and Safety Study of QAW039 in the Treatment of Patients With Moderate to Severe Atopic Dermatitis. | Biotech Hunter

Enrollment

103

Participants

Timeline

Start Date

June 30, 2013

Primary Completion Date

November 30, 2014

Study Completion Date

November 30, 2014

Conditions

Atopic Dermatitis

Interventions

DRUG

QAW039

Capsules

DRUG

Placebo

Capsules

Trial Locations (18)

1200

Novartis Investigative Site, Brussels

1612

Novartis Investigative Site, Sofia

2606

Novartis Investigative Site, Phillip

3000

Novartis Investigative Site, Leuven

4000

Novartis Investigative Site, Liège

4001

Novartis Investigative Site, Durban

4102

Novartis Investigative Site, Woolloongabba

4217

Novartis Investigative Site, Benowa

10098

Novartis Investigative Site, Berlin

10117

Novartis Investigative Site, Berlin

48149

Novartis Investigative Site, Münster

53105

Novartis Investigative Site, Bonn

Unknown

Novartis Investigative Site, Vienna

Novartis Investigative Site, Groningen

01307

Novartis Investigative Site, Dresden

1105 AZ

Novartis Investigative Site, Amsterdam

3508 GA

Novartis Investigative Site, Utrecht

011461

Novartis Investigative Site, Bucharest